Cargando…
Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
Autores principales: | Mecca, Caterina, Bertaglia, Valentina, Novello, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797454/ https://www.ncbi.nlm.nih.gov/pubmed/35117068 http://dx.doi.org/10.21037/tcr.2018.08.23 |
Ejemplares similares
-
Angiogenetic Factors in Chronic Subdural Hematoma Development
por: Petrov, Andrey, et al.
Publicado: (2022) -
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020) -
Inhibition of angiogenetic macrophages reduces disc degeneration-associated pain
por: Hou, Yang, et al.
Publicado: (2022) -
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions
por: Berardi, Rossana, et al.
Publicado: (2020) -
Organizing for collaboration: An actor‐oriented architecture in ImproveCareNow
por: Seid, Michael, et al.
Publicado: (2019)